Novartis Ag

Irm LLC

Other

Tetsuo Uno

Bernhard Hubert Geierstanger

Yunho Jin

Weijia Ou

Jan Grunewald

Xing Wang

Yongqin Wan

Qiang Ding

Pierre-Yves Michellys

Thomas H Marsilje, Iii

Bei Chen

Wei Pei

Nathanael Schiander Gray

Yi Liu

Matthew T Burger

Bing Li

Susan E Cellitti

Tao Jiang

Shailaja Kasibhatla

Guobao Zhang

Taebo Sim

Xueshi Hao

Pingda Ren

Shifeng Pan

Steven Lee Bender

Scott Glaser

Michael P Cooke

Kathrin Tissot

Xia Wang

Shuli You

Mark Knuth

Glen Spraggon

Siew Ho Schleyer

Catrin Finner

Sarah Rue

Anthony E Boitano

Ben Wen

Anna Galkin

Si Tuen Lee-Hoeflich

HongNgoc Thi Pham

Tiffany Crossgrove

Hsien-Po Chiu

Hyun Soo Lee

Lintong Li

Sabine Rottmann

Tracy Charlton

Pascal Furet

Paul William Manley

Guido Bold

Marc Lang

Giorgio Caravatti

Vito Guagnano

Werner Breitenstein

Tom Yao-Hsiang Wu

Joseph Schoepfer

Timothy Z Hoffman

Wenshuo Lu

Carsten Spanka

Barun Okram

Alex Cortez

Xu Wu

Carole Pissot Soldermann

Yahua Liu

Qihui Jin

Jianwei Che

S Frank Yan

This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

Anti-CCR7 antibody drug conjugates

The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.

Antibody drug conjugates for ablating hematopoietic stem cells

The present invention provides specific sites for modifying antibodies or antibody fragments by replacing at least one native amino acid in the constant region of a parental antibody or antibody fragment with cysteine, which can be used as a site of attachment for a payload or linker-payload combination.

Specific sites for modifying antibodies to make immunoconjugates

Provided herein are antibody conjugates comprising toll-like receptor agonists and the use of such conjugates for the treatment of cancer. In some embodiments, the conjugates comprise anti-HER2 antibodies.

Antibody conjugates comprising toll-like receptor agonist

Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.

Cytotoxic peptides and conjugates thereof

The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (A), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.e Antibody Drug Conjugates), pharmaceutical compositions comprising such cyclic peptides immunoconjugates, compositions comprising such cyclic peptides immunoconjugates with a therapeutic co-agent and methods of treatment using such cyclic peptides immunoconjugates: 

Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase

Disclosed herein are novel compounds of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel compound linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.

The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (I), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.e Antibody Drug Conjugates), pharmaceutical compositions comprising such cyclic peptides immunoconjugates, compositions comprising such cyclic peptides immunoconjugates with a therapeutic co-agent and methods of treatment using such cyclic peptides immunoconjugates: 

Auristatin derivatives and conjugates thereof

Disclosed herein is pyrroline-carboxy-lysine (PCL), a pyrrolysine analog, which is a natural, biosynthetically generated amino acid, and methods for biosynthetically generating PCL. Also disclosed herein are proteins, polypeptides and peptides that have PCL incorporated therein and methods for incorporating PCL into such proteins, polypeptides and peptides. Also disclosed herein is the site-specific derivatization of proteins, polypeptides and peptides having PCL or pyrrolysine incorporated therein. Also disclosed herein is the crosslinking of proteins, polypeptides and peptides having PCL or pyrrolysine incorporated therein.

Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues

Growing community of inventors

San Diego, CA, United States of America

Tetsuo Uno